CompletedNot Applicable

The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

China46 participantsStarted 2020-08-15

Plain-language summary

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis).

Who can participate

Age range17 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. age \<18 years old
✓. meet the diagnostic criteria of disease classification
✓. HIV negative;Negative for Hepatitis B Virus and Hepatitis C Virus.

Exclusion criteria

✕. heart failure (cardiac function ≥ grade III NYHA)
✕. liver insufficiency (upper limit of normal range of transaminase \> 2 times)
✕. renal insufficiency (creatinine clearance ≤30ml/min)
✕. acute or severe infections such as bacteremia and sepsis
✕. malignant tumor
✕. high-dose steroid pulse therapy or intravenous injection of glucocorticoids in the last 1 month;Rituximab, infliximab or other biological agents were used
✕. mental disorders or any other chronic illness or substance abuse may interfere with the ability to comply with agreements or provide information
✕. Inability to comply with IL-2 treatment regimen.

What they're measuring

Change in steroid dose and immunosuppressor dose at 1 year compared to control group

Timeframe: 1 year

Trial details

NCT IDNCT04397107

SponsorThe First Hospital of Jilin University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-31

View on ClinicalTrials.gov More Systemic Lupus Erythematosus trials